Cytek Biosciences Q2 revenue slightly misses estimates
CTKB•Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Slight Miss* | $48.14 mln | $48.61 mln (3 Analysts) |
| Q2 Net Loss | $12.16 mln | ||
| Q2 Adjusted EBITDA | -$1.54 mln | ||
| Q2 Adjusted Gross Margin | 59% | ||
| Q2 Pretax Loss | $11.64 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
- Wall Street's median 12-month price target for Cytek Biosciences, Inc. is $5.25, about 22.7% above its August 4 closing price of $4.28
Quarterly results
- Cell analysis solutions firm's Q2 revenue rose 6% yr/yr, slightly missing analyst expectations
- Company posted a wider Q2 net loss, with adjusted EBITDA turning negative
- Cytek raised full-year 2026 revenue outlook midpoint by $1 mln
